GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Bimatoprost is under clinical development by Laboratoires Thea and currently in Phase III for Ocular Hypertension.

The OHTS-EGPS prediction model provides modestly predictive data for glaucoma conversion for some patients with ocular hypertension.

Purpose: To review the literature regarding ocular hypertension following intravitreal antivascular endothelial growth factor therapy, and to propose a novel mechanism for the development of ...

Glaucoma, the second leading cause of blindness globally, affects millions and is projected to reach 111.8 million cases by ...

Our purpose is to update the comprehensive ophthalmologist about the results of the Ocular Hypertension Treatment Study and the current clinical management of ocular hypertension. In the Ocular ...

Glaucoma is a progressive eye disorder characterized by fluid buildup inside the eye, causing ocular hypertension. By 2040, ...

Some patients with ocular hypertension who develop primary open angle glaucoma experience rapid visual field loss.

Pravin U. Dugel, MD, Ocular’s Executive Chairman, President and CEO, will provide an update regarding the enrollment status of SOL-R, the Company’s second registrational trial of AXPAXLI™ for the ...